Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in:

Open Access 01-12-2024 | Review

CAR-armored-cell therapy in solid tumor treatment

Authors: Yan Liu, Lin Xiao, Mingxuan Yang, Xuemei Chen, Hongyue Liu, Quanxing Wang, Meng Guo, Jianhua Luo

Published in: Journal of Translational Medicine | Issue 1/2024

Login to get access

Abstract

Over the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a revolutionary immunotherapeutic approach to combat cancer. This therapy constructs a CAR on the surface of T cells through genetic engineering techniques. The CAR is formed from a combination of antibody-derived or ligand-derived domains and T-cell receptor (TCR) domains. This enables T cells to specifically bind to and activate against tumor cells. However, the efficacy of CAR-T cells in solid tumors remains inconclusive due to several challenges such as poor tumor trafficking, infiltration, and the immunosuppressive tumor microenvironment (TME). In response, CAR natural killer (CAR-NK) and CAR macrophages (CAR-M) have been developed as complementary strategies for solid tumors. CAR-NK cells do not require HLA compatibility, demonstrate reduced toxicity, and are thus seen as potential substitutes for CAR-T cells. Furthermore, CAR-M immunotherapy is also being researched and has shown phagocytic capabilities and tumor-antigen presentation. This study discusses the features, advantages, and limitations of CAR-T, CAR-NK, and CAR-M cells in the treatment of solid tumors and suggests prospective solutions for enhancing the efficacy of CAR host-cell-based immunotherapy.
Literature
1.
Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004;305:200–5.PubMedCrossRef
2.
Wallace HM, Hergenrother PJ, Sadler PJ. Molecular medicine and cancer. Chem Soc Rev. 2015;44:8771–2.PubMedCrossRef
3.
Gubin MM. Cancer Immunology and Immunotherapy: taking a place in mainstream oncology keystone Symposia Meeting Summary. Cancer Immunol Res. 2017;5:434–8.PubMedCrossRef
4.
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21.PubMedPubMedCentralCrossRef
5.
Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635–48.PubMedCrossRef
6.
Benmebarek M-R et al. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T cells. Int J Mol Sci 20, (2019).
7.
8.
9.
10.
Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147–67.PubMedCrossRef
11.
Chiesa R, et al. Base-edited CAR7 T cells for relapsed T-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2023;389:899–910.PubMedCrossRef
12.
13.
Spiegel JY, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419–31.PubMedPubMedCentralCrossRef
14.
15.
16.
Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139:2737–46.PubMedCrossRef
17.
Brown CE, et al. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma. Neurooncology. 2022;24:1318–30.
18.
Zhang Y, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147:3725–34.PubMedCrossRef
19.
20.
Gastric Cancer. CAR T-cell target Antigen ID’d. Cancer Discov. 2021;11:2954.CrossRef
21.
Lamers CH, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21:904–12.PubMedPubMedCentralCrossRef
22.
Narayan V, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724–34.PubMedPubMedCentralCrossRef
23.
Yankelevich M et al. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells. J Immunother Cancer 12, (2024).
24.
Lesch S, et al. Determinants of response and resistance to CAR T cell therapy. Sem Cancer Biol. 2020;65:80–90.CrossRef
25.
Flugel CL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49–62.PubMedCrossRef
26.
Yan Z, et al. Characteristics and risk factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Front Immunol. 2021;12:611366.PubMedPubMedCentralCrossRef
27.
Maus MV et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 8, (2020).
28.
Lee DW, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and neurologic toxicity Associated with Immune Effector cells. Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2019;25:625–38.CrossRef
29.
Dagher OK, Posey AD. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24:1994–2007.PubMedCrossRef
30.
Pan K, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Experimental Clin Cancer Research: CR. 2022;41:119.PubMedCentralCrossRef
31.
32.
Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.PubMedCrossRef
33.
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–99.PubMedCrossRef
34.
Hu Z, et al. LunX-CAR T Cells as a targeted therapy for Non-small Cell Lung Cancer. Mol Therapy Oncolytics. 2020;17:361–70.CrossRef
35.
Batra SA, et al. Glypican-3-Specific CAR T cells coexpressing IL15 and IL21 have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020;8:309–20.PubMedPubMedCentralCrossRef
36.
Jiang H, et al. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the treatment of gastric Cancer. J Natl Cancer Inst. 2019;111:409–18.PubMedCrossRef
37.
Li H, et al. CAIX-specific CAR-T cells and Sunitinib Show Synergistic effects against metastatic renal Cancer models. J Immunotherapy (Hagerstown Md: 1997). 2020;43:16–28.
38.
39.
Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12:14.PubMedPubMedCentralCrossRef
40.
41.
42.
Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995;358:1–3.PubMedCrossRef
43.
44.
Brand A, et al. LDHA-Associated Lactic Acid Production blunts Tumor Immunosurveillance by T and NK Cells. Cell Metabol. 2016;24:657–71.CrossRef
45.
Pilon-Thomas S, et al. Neutralization of Tumor Acidity improves antitumor responses to Immunotherapy. Cancer Res. 2016;76:1381–90.PubMedCrossRef
46.
Cui J, et al. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. Neurooncology. 2019;21:1436–46.
47.
Fultang L, et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood. 2020;136:1155–60.PubMedPubMedCentralCrossRef
48.
49.
50.
Cassetta L et al. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J Immunother Cancer 8, (2020).
51.
Choe JH et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med 13, (2021).
52.
Hyrenius-Wittsten A et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med 13, (2021).
53.
Srivastava S et al. Logic-gated ROR1 Chimeric Antigen Receptor Expression Rescues T cell-mediated toxicity to normal tissues and enables selective Tumor Targeting. Cancer Cell 35, (2019).
54.
Abbott RC, Hughes-Parry HE, Jenkins MR. To go or not to go? Biological logic gating engineered T cells. J Immunother Cancer 10, (2022).
55.
Zhao Y et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol, (2024).
56.
57.
Wang L, et al. Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology. 2016;5:e1211218.PubMedPubMedCentralCrossRef
58.
Ahmed N, et al. Human epidermal growth factor receptor 2 (HER2) -Specific chimeric Antigen receptor-modified T cells for the Immunotherapy of HER2-Positive sarcoma. J Clin Oncol. 2015;33:1688–96.PubMedPubMedCentralCrossRef
59.
Makkouk A et al. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother Cancer 9, (2021).
60.
Townsend MH, Shrestha G, Robison RA. O’Neill, the expansion of targetable biomarkers for CAR T cell therapy. J Experimental Clin Cancer Research: CR. 2018;37:163.PubMedCentralCrossRef
61.
62.
63.
64.
65.
66.
67.
Zheng X, et al. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol. 2022;19:192–209.PubMedPubMedCentralCrossRef
68.
Brog RA, et al. Superkine IL-2 and IL-33 armored CAR T cells reshape the Tumor Microenvironment and reduce growth of multiple solid tumors. Cancer Immunol Res. 2022;10:962–77.PubMedPubMedCentralCrossRef
69.
Zhu I, Piraner DI, Roybal KT. Synthesizing a smarter CAR T cell: Advanced Engineering of T-cell immunotherapies. Cancer Immunol Res. 2023;11:1030–43.PubMedPubMedCentralCrossRef
70.
Lv M, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020;30:966–79.PubMedPubMedCentralCrossRef
71.
Nicoli F, Paul S, Appay V. Harnessing the induction of CD8 + T-Cell responses through metabolic regulation by Pathogen-Recognition-receptor triggering in Antigen presenting cells. Front Immunol. 2018;9:2372.PubMedPubMedCentralCrossRef
72.
Johnson LR et al. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell 184, (2021).
73.
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403.PubMedCrossRef
74.
Wang L-CS, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154–66.PubMedCrossRef
75.
76.
Lanitis E et al. VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. J Immunother Cancer 9, (2021).
77.
Tran TM et al. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1. J Immunother Cancer 12, (2024).
78.
Tang N et al. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 5, (2020).
79.
80.
Kohlhapp FJ, Kaufman HL, Pathways M. Mechanism of action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clin cancer Research: Official J Am Association Cancer Res. 2016;22:1048–54.CrossRef
81.
82.
Evgin L, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022;14:eabn2231.PubMedPubMedCentralCrossRef
83.
Park AK et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med 12, (2020).
84.
Wang G, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31:134–53.PubMedCrossRef
85.
Ma L et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, (2023).
86.
87.
Reinhard K, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367:446–53.PubMedCrossRef
88.
Mackensen A, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29:2844–53.PubMedPubMedCentralCrossRef
89.
90.
Yamaguchi Y et al. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163 + M2 macrophages. J Immunother Cancer 10, (2022).
91.
92.
Rezvan A, et al. Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat cancer. 2024;5:1010–23.PubMedCrossRef
93.
Xia Z et al. Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders. Nat Biomedical Eng, (2024).
94.
95.
Hort S, et al. Widely available autologous CAR-T cell therapy - Artificial intelligence and automation enabling the Smart Manufacturing Hospital. Front Med. 2022;9:913287. Toward Rapid.CrossRef
96.
Naghizadeh A, et al. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes. PLoS Comput Biol. 2022;18:e1009883.PubMedPubMedCentralCrossRef
97.
98.
Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200–18.PubMedCrossRef
99.
Lamers-Kok N, et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol. 2022;15:164.PubMedPubMedCentralCrossRef
100.
Wang Z, et al. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D. Cancer Immunol Immunother. 2017;66:537–48.PubMedPubMedCentralCrossRef
101.
Kmiecik J, Zimmer J, Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J Neurooncol. 2014;116:1–9.PubMedCrossRef
102.
Dagher OK, Posey AD Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24:1994–2007.PubMedCrossRef
103.
Teng KY, et al. Off-the-Shelf prostate Stem Cell Antigen-Directed chimeric Antigen receptor Natural Killer Cell Therapy to treat pancreatic Cancer. Gastroenterology. 2022;162:1319–33.PubMedCrossRef
104.
Imamura M, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood. 2014;124:1081–8.PubMedCrossRef
105.
Bodden M et al. Co-expression of an IL-15 superagonist facilitates Self-Enrichment of GD2-Targeted CAR-NK cells and mediates potent cell killing in the absence of IL-2. Cancers (Basel) 15, (2023).
106.
Lu C, et al. A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis. Mol Immunol. 2020;122:200–6.PubMedCrossRef
107.
Ng YY, Tay JCK, Wang S. CXCR1 expression to improve Anti-cancer Efficacy of Intravenously Injected CAR-NK cells in mice with peritoneal xenografts. Mol Ther Oncolytics. 2020;16:75–85.PubMedCrossRef
108.
Muller N, et al. Engineering NK cells modified with an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1alpha-secreting Glioblastoma. J Immunother. 2015;38:197–210.PubMedPubMedCentralCrossRef
109.
Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived natural killer cells Engineered with chimeric Antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23:181–e192185.PubMedPubMedCentralCrossRef
110.
Wang Z, et al. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-betaR II and NKG2D. Cancer Immunol Immunother. 2017;66:537–48.PubMedPubMedCentralCrossRef
111.
Douanne T, Griffiths GM. Cytoskeletal control of the secretory immune synapse. Curr Opin Cell Biol. 2021;71:87–94.PubMedCrossRef
112.
Chockley PJ, Ibanez-Vega J, Krenciute G, Talbot LJ, Gottschalk S. Synapse-tuned CARs enhance immune cell anti-tumor activity. Nat Biotechnol, (2023).
113.
114.
Klopotowska M, et al. PRDX-1 supports the survival and antitumor activity of primary and CAR-Modified NK cells under oxidative stress. Cancer Immunol Res. 2022;10:228–44.PubMedCrossRef
115.
Nachef M, Ali AK, Almutairi SM, Lee SH. Targeting SLC1A5 and SLC3A2/SLC7A5 as a potential strategy to strengthen Anti-tumor Immunity in the Tumor Microenvironment. Front Immunol. 2021;12:624324.PubMedPubMedCentralCrossRef
116.
Chen X, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7:27764–77.PubMedPubMedCentralCrossRef
117.
118.
Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9:122–39.PubMedCrossRef
119.
120.
Huang SW, et al. BiTE-Secreting CAR-gammadeltaT as a dual targeting strategy for the treatment of solid tumors. Adv Sci (Weinh). 2023;10:e2206856.PubMedCrossRef
121.
Guha P, Heatherton KR, O’Connell KP, Alexander IS, Katz SC. Assess Future Solid Tumor Immunotherapy Biomedicines 10, (2022).
122.
Siegler EL, et al. Combination Cancer Therapy using chimeric Antigen receptor-Engineered Natural Killer cells as drug carriers. Mol Ther. 2017;25:2607–19.PubMedPubMedCentralCrossRef
123.
Cao G, et al. Tumor therapeutics work as stress inducers to enhance Tumor Sensitivity to Natural Killer (NK) cell cytolysis by Up-regulating NKp30 ligand B7-H6. J Biol Chem. 2015;290:29964–73.PubMedPubMedCentralCrossRef
124.
125.
126.
Kang M, et al. Nanocomplex-mediated in vivo programming to chimeric Antigen Receptor-M1 macrophages for Cancer Therapy. Adv Mater. 2021;33:e2103258.PubMedCrossRef
127.
Schildberger A, Rossmanith E, Eichhorn T, Strassl K, Weber V. Monocytes, peripheral blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns following stimulation with lipopolysaccharide. Mediators Inflamm 2013, 697972 (2013).
128.
129.
Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577.PubMedPubMedCentralCrossRef
130.
131.
Lee HW, Choi HJ, Ha SJ, Lee KT, Kwon YG. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim Biophys Acta. 2013;1835:170–9.PubMed
132.
Santoni M, et al. Re: human chimeric Antigen receptor macrophages for Cancer Immunotherapy. Eur Urol. 2021;79:887–9.PubMedCrossRef
133.
van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD16 + macrophages in antitumor cytotoxicity. Lab Invest. 1992;67:166–74.PubMed
134.
135.
Zhang W, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121:837–45.PubMedPubMedCentralCrossRef
136.
Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720–4.PubMedPubMedCentralCrossRef
137.
Morrissey MA et al. Chimeric antigen receptors that trigger phagocytosis. Elife 7, (2018).
138.
139.
Duan Z, Li Z, Wang Z, Chen C, Luo Y. Chimeric antigen receptor macrophages activated through TLR4 or IFN-γ receptors suppress breast cancer growth by targeting VEGFR2. Cancer Immunol Immunotherapy: CII. 2023;72:3243–57.PubMedPubMedCentralCrossRef
140.
Bobadilla S, Sunseri N, Landau NR. Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. Gene Ther. 2013;20:514–20.PubMedCrossRef
141.
142.
Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the Tumor Microenvironment. Cell Metabol. 2019;30:36–50.CrossRef
143.
Cohen N, et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of chitinase 3-like 1. Oncogene. 2017;36:4457–68.PubMedPubMedCentralCrossRef
144.
145.
Lei A, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2024;25:102–16.PubMedCrossRef
146.
147.
Trouplin V et al. Bone marrow-derived macrophage production. J Vis Exp, e50966 (2013).
148.
149.
150.
151.
Hynes RO, Naba A. Overview of the matrisome–an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol. 2012;4:a004903.PubMedPubMedCentralCrossRef
152.
Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol. 2003;54:371–89.PubMedCrossRef
153.
Mburu YK, Wang J, Wood MA, Walker WH, Ferris RL. CCR7 mediates inflammation-associated tumor progression. Immunol Res. 2006;36:61–72.PubMedCrossRef
154.
Niu Z, et al. Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity. J Pathol. 2021;253:247–57.PubMedCrossRef
155.
156.
Pierini S, et al. Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models. Cancer Res 81. Abstract 2021;63:63–63.CrossRef
157.
158.
Hu L, et al. Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate. Cell Death Dis. 2020;11:281.PubMedPubMedCentralCrossRef
159.
Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340–55.PubMedCrossRef
160.
Huo Y, et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J Translational Med. 2023;21:225.CrossRef
161.
Abdou Y et al. Abstract PO2-04-08: Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 positive metastatic breast cancer and other HER2 overexpressing solid tumors. Cancer Research 84, PO2-04-08-PO02-04-08 (2024).
162.
Burger MC, et al. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neurooncology. 2023;25:2058–71.
163.
Zhang X, et al. Cytokine release Syndrome after Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer patient: a Case Report. Cell Transplant. 2022;31:9636897221094244.PubMedCrossRef
164.
Metadata
Title
CAR-armored-cell therapy in solid tumor treatment
Authors
Yan Liu
Lin Xiao
Mingxuan Yang
Xuemei Chen
Hongyue Liu
Quanxing Wang
Meng Guo
Jianhua Luo
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2024
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-024-05903-3

Other articles of this Issue 1/2024

Epidermal stem cells: skin surveillance and clinical perspective

  • Open Access
  • Review

The ANGPTL4-HIF-1α loop: a critical regulator of renal interstitial fibrosis

The interaction of platelet-related factors with tumor cells promotes tumor metastasis

Several implications for the pathogenesis and treatment of thrombosis in PNH patients according to multiomics analysis

Development and validation of predictive models for myopia onset and progression using extensive 15-year refractive data in children and adolescents

Senescent fibroblast facilitates re-epithelization and collagen deposition in radiation-induced skin injury through IL-33-mediated macrophage polarization

  • Open Access
  • Research

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
 

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Register your interest now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits